Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:Addition of 2-(ethylamino)acetonitrile group to nitroxoline results in significantly improved anti-tumor activity in vitro and in vivo
Authors:ID Mitrović, Ana (Author)
ID Sosič, Izidor (Author)
ID Kos, Špela (Author)
ID Lampreht Tratar, Urša (Author)
ID Breznik, Barbara (Author)
ID Kranjc Brezar, Simona (Author)
ID Mirković, Bojana (Author)
ID Gobec, Stanislav (Author)
ID Lah Turnšek, Tamara (Author)
ID Čemažar, Maja (Author)
ID Serša, Gregor (Author)
ID Kos, Janko (Author)
Files:.pdf PDF - Presentation file, download (4,30 MB)
MD5: D122E245A831A4E6A8A2A7DE4054FBC4
 
URL URL - Source URL, visit https://doi.org/10.18632/oncotarget.19296
 
Language:English
Typology:1.01 - Original Scientific Article
Organization:Logo NIB - National Institute of Biology
Abstract:Lysosomal cysteine peptidase cathepsin B, involved in multiple processes associated with tumor progression, is validated as a target for anti-cancer therapy. Nitroxoline, a known antimicrobial agent, is a potent and selective inhibitor of cathepsin B, hence reducing tumor progression in vitro and in vivo. In order to further improve its anti-cancer properties we developed a number of derivatives using structure-based chemical synthesis. Of these, the 7-aminomethylated derivative (compound 17) exhibited significantly improved kinetic properties over nitroxoline, inhibiting cathepsin B endopeptidase activity selectively. In the present study, we have evaluated its anti-cancer properties. It was more effective than nitroxoline in reducing tumor cell invasion and migration, as determined in vitro on two-dimensional cell models and tumor spheroids, under either endpoint or real time conditions. Moreover, it exhibited improved action over nitroxoline in impairing tumor growth in vivo in LPB mouse fibrosarcoma tumors in C57Bl/6 mice. Taken together, the addition of a 2-(ethylamino)acetonitrile group to nitroxoline at position 7 significantly improves its pharmacological characteristics and its potential for use as an anti-cancer drug.
Keywords:nitroxoline derivative, cathepsin B, inhibition, tumor invasion, cell migration
Publication status:Published
Publication version:Version of Record
Publication date:17.07.2017
Year of publishing:2017
Number of pages:str. 59136-59147
Numbering:Vol. 8, no. 35
PID:20.500.12556/DiRROS-19722 New window
UDC:577.2
ISSN on article:1949-2553
DOI:10.18632/oncotarget.19296 New window
COBISS.SI-ID:4360305 New window
Note:Nasl. z nasl. zaslona; Opis vira z dne 9. 8. 2017;
Publication date in DiRROS:26.07.2024
Views:4
Downloads:4
Metadata:XML RDF-CHPDL DC-XML DC-RDF
:
Copy citation
  
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Oncotarget
Shortened title:Oncotarget
Publisher:Impact Journals
ISSN:1949-2553
COBISS.SI-ID:3833969 New window

Document is financed by a project

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:J4-5529-2013
Name:Nitroksolin in njegovi derivati kot nova protitumorska zdravila

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:P4-0127-2015
Name:Farmacevtska biotehnologija: znanost za zdravje

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:Z1-7181-2016
Name:Strukturno podprta optimizacija na nitroksolinu osnovanih zaviralcev katepsina B kot potencialnih zdravil za zdravljenje raka

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.

Back